Literature DB >> 23354599

Immune effects of optimized DNA vaccine and protective effects in a MPTP model of Parkinson's disease.

Zhongmei Chen1, Yunpeng Yang, Xu Yang, Changqing Zhou, Fengqun Li, Peng Lei, Ling Zhong, Xin Jin, Guoguang Peng.   

Abstract

It has been suggested that DNA vaccine plays a protective effect on degenerative diseases in the central nervous system (CNS), the Parkinson's disease (PD) included. In this study, we assessed the immune effects of optimized DNA vaccine (pVAX1-IL-4/SYN-B) in the C57BL/6 mice by ELISA, and immunohistochemistry. We also evaluated the neuroprotective effect of pVAX1-IL-4/SYN-B in MPTP model of Parkinson's disease, using behavioral methods, immunohistochemistry and western blot. We found that alphα-synuclein (α-syn) antibody significantly increased, IL-4 increased and IFN-r reduced in the serum of immunized C57BL/6 mice in optimized DNA vaccine group. The immune serum of mice specifically combined with the α-syn positive inclusion bodies in the brain of PD model mice. The preventive immunization with optimized DNA vaccine made the motor symptoms improved significantly, the apoptosis of tyrosine hydroxylase (TH) neuron and cyclooxygenase-2 (COX-2) expression significantly decreased in MPTP model mice. These results suggest that optimized DNA vaccine can make immunized mice produce high titers of specific α-syn antibody, mainly causing the humoral immune response; preventive immunization with optimized DNA vaccine can play neuroprotective and anti-inflammatory effects on mice suffering from the sub-acute MPTP Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23354599     DOI: 10.1007/s10072-012-1284-6

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  48 in total

1.  Prevention of onset of Parkinson's disease by in vivo gene transfer of human hepatocyte growth factor in rodent model: a model of gene therapy for Parkinson's disease.

Authors:  H Koike; A Ishida; M Shimamura; S Mizuno; T Nakamura; T Ogihara; Y Kaneda; R Morishita
Journal:  Gene Ther       Date:  2006-06-22       Impact factor: 5.250

2.  Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

Authors:  Eliezer Masliah; Edward Rockenstein; Anthony Adame; Michael Alford; Leslie Crews; Makoto Hashimoto; Peter Seubert; Michael Lee; Jason Goldstein; Tamie Chilcote; Dora Games; Dale Schenk
Journal:  Neuron       Date:  2005-06-16       Impact factor: 17.173

3.  Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease.

Authors:  Ken-ichiro Fukuchi; Kazuki Tahara; Hong-Duck Kim; J Adam Maxwell; Terry L Lewis; Mary Ann Accavitti-Loper; Helen Kim; Selvarangan Ponnazhagan; Robert Lalonde
Journal:  Neurobiol Dis       Date:  2006-09       Impact factor: 5.996

4.  Intravenous infusion of GDNF gene-modified human umbilical cord blood CD34+ cells protects against cerebral ischemic injury in spontaneously hypertensive rats.

Authors:  Yali Ou; Seongjin Yu; Yuji Kaneko; Naoki Tajiri; Eunkyung Cate Bae; Sonia H Chheda; Christine E Stahl; Tianlun Yang; Li Fang; Kei Hu; Cesar V Borlongan; Guolong Yu
Journal:  Brain Res       Date:  2010-10-01       Impact factor: 3.252

Review 5.  Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis.

Authors:  Joshua J Gagne; Melinda C Power
Journal:  Neurology       Date:  2010-03-23       Impact factor: 9.910

6.  Synergistic interactions between NMDA-antagonists and L-dopa on activity in MPTP-treated mice.

Authors:  A Fredriksson; C Gentsch; T Archer
Journal:  J Neural Transm Gen Sect       Date:  1994

7.  Alleviation of Abeta-induced cognitive impairment by ultrasound-mediated gene transfer of HGF in a mouse model.

Authors:  D Takeuchi; N Sato; M Shimamura; H Kurinami; S Takeda; M Shinohara; S Suzuki; M Kojima; T Ogihara; R Morishita
Journal:  Gene Ther       Date:  2008-02-21       Impact factor: 5.250

8.  Cyclooxygenase and neuroinflammation in Parkinson's disease neurodegeneration.

Authors:  Anna L Bartels; Klaus L Leenders
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

9.  Decreased inflammation and augmented expression of trophic factors correlate with MOG-induced neuroprotection of the injured nigrostriatal system in the murine MPTP model of Parkinson's disease.

Authors:  I Kurkowska-Jastrzebska; E Bałkowiec-Iskra; A Ciesielska; I Joniec; A Cudna; M M Zaremba; A Członkowski; A Członkowska
Journal:  Int Immunopharmacol       Date:  2009-03-13       Impact factor: 4.932

10.  The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.

Authors:  Oleg S Gorbatyuk; Shoudong Li; Layla F Sullivan; Weijun Chen; Galina Kondrikova; Fredric P Manfredsson; Ronald J Mandel; Nicholas Muzyczka
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-04       Impact factor: 11.205

View more
  3 in total

Review 1.  Gene-based vaccines and immunotherapeutic strategies against neurodegenerative diseases: Potential utility and limitations.

Authors:  Jeremy J Kudrna; Kenneth E Ugen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Emerging Therapeutic Strategies for Parkinson's Disease and Future Prospects: A 2021 Update.

Authors:  Noha A Gouda; Ahmed Elkamhawy; Jungsook Cho
Journal:  Biomedicines       Date:  2022-02-03

Review 3.  Toward a Disease-Modifying Therapy of Alpha-Synucleinopathies: New Molecules and New Approaches Came into the Limelight.

Authors:  Matthew Upcott; Kirill D Chaprov; Vladimir L Buchman
Journal:  Molecules       Date:  2021-12-03       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.